Old Web
English
Sign In
Acemap
>
authorDetail
>
Shanghai Junshi Biosciences
Shanghai Junshi Biosciences
Oncology
Internal medicine
Medicine
Biomarker Analysis
Pathology
5
Papers
16
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (5)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
JUPITER-02: Randomized, double-blind, phase III study of toripalimab or placebo plus gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC).
2021
Journal of Clinical Oncology
Rui Hua Xu
Hai Qiang Mai
Qiu Yan Chen
Dongping Chen
Chaosu Hu
Kunyu Yang
Jiyu Wen
Jingao Li
Ying-rui Shi
Feng Jin
Ruilian Xu
Jianji Pan
Shenhong Qu
P. Li
Chunhong Hu
Yi-Chun Liu
Yi Jiang
Xia He
Hung-Ming Wang
Wan-Teck Lim
Coherus Biosciences
Shanghai Junshi Biosciences
Show All
Source
Cite
Save
Citations (3)
Overall survival and biomarker analysis of a phase Ib combination study of toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) with axitinib in patients with metastatic mucosal melanoma.
2020
Journal of Clinical Oncology
Xinan Sheng
Xieqiao Yan
Zhihong Chi
Lu Si
Chuanliang Cui
Bixia Tang
Siming Li
Lili Mao
Bin Lian
Xuan Wang
Xue Bai
Li Zhou
Yan Kong
Jie Dai
Keith T. Flaherty
Jun Guo
Shanghai Junshi Biosciences
Show All
Source
Cite
Save
Citations (5)
A multi-center phase II study of toripalimab with chemotherapy in patients with EGFR mutant advanced NSCLC patients resistant to EGFR TKIs: Efficacy and biomarker analysis.
2020
Journal of Clinical Oncology
Shengxiang Ren
Jie Zhang
Yanqiu Zhao
Xiaoqian Mu
Jianying Zhou
Zhang Bao
Yun Fan
Yanjun Xu
Yongqian Shu
Renhua Guo
Xiaoqing Liu
Hong Wang
Helong Zhang
Lin Deng
Ningqiang Ma
Jianxing He
Yalei Zhang
Caicun Zhou
Shanghai Junshi Biosciences
Show All
Source
Cite
Save
Citations (6)
Clinical response and biomarker analysis of a phase II basket trial of toripalimab, a PD-1 mAb in combination with standard chemotherapy as a first-line treatment for patients with solid tumors.
2020
Journal of Clinical Oncology
Chao Ren
Xiao Li Wei
Nong Xu
Lin Shen
Guanghai Dai
Xianglin Yuan
Ye Chen
Shujun Yang
Jianhua Shi
Xichun Hu
Xiaoyan Lin
Qingyuan Zhang
Jifeng Feng
Yi Ba
Yunpeng Liu
Wei Liu
Yongqian Shu
Rui Hua Xu
Shanghai Junshi Biosciences
Show All
Source
Cite
Save
Citations (1)
Clinical response and biomarker analysis of POLARIS-02 a phase II study of toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) in patients with metastatic nasopharyngeal carcinoma.
2020
Journal of Clinical Oncology
Fenghua Wang
Xiao Li Wei
Jifeng Feng
Qi Li
Nong Xu
Xichun Hu
Wangjun Liao
Yi Jiang
Xiaoyan Lin
Qingyuan Zhang
Xianglin Yuan
Haixin Huang
Ye Chen
Guanghai Dai
Jianhua Shi
Lin Shen
Shujun Yang
Yongqian Shu
Yunpeng Liu
Rui Hua Xu
Shanghai Junshi Biosciences
Show All
Source
Cite
Save
Citations (1)
1